Abstract
Rosacea is a chronic inflammatory facial condition that has traditionally been treated with topical therapies, oral antibiotics or both. The use of oral antibiotics at conventional doses can lead to antimicrobial resistance, alterations in the balance of normal microflora and potentially serious side effects. Anti-inflammatory dose doxycycline is a novel approach to the treatment of rosacea that separates the anti-inflammatory effects of doxycycline from its antimicrobial properties by limiting plasma concentrations to a range below the minimal inhibitory concentrations of susceptible bacteria. This review describes the evidence supporting the use of anti-inflammatory dose doxycycline in the treatment of rosacea, explores its mechanism of action and considers its place in therapy.
Financial & competing interests disclosure
The author is a consultant, speaker and/or clinical research investigator for many dermatologic pharmaceutical manufacturers, including the manufacturer of an anti-inflammatory dose doxycycline product. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.